TP53 and prostate adenocarcinoma: Additionally, we performed a stratified analysis of PRAD based on patient race, age, lymphatic metastasis status, and TP53 mutation status, showing that the TMPRSS2 promoter methylation levels of older people, the lymphatic metastasis group, and the TP53 mutation group were lower than that of the control in PRAD (Figures 4B–E), suggesting that PRAD TMPRSS2 promoter methylation might be activated and increase its level.